

## Alcohol and Cancer

Guest Editors:

**Prof. Dr. Helmut K. Seitz**

Distinguished Professor of  
Medicine, Gastroenterology and  
Alcohol Research, University of  
Heidelberg, Heidelberg, Germany

helmut\_karl.seitz@urz.uni-  
heidelberg.de

**Prof. Dr. Sebastian Mueller**

Professor of Medicine, University  
of Heidelberg, Heidelberg,  
Germany

sebastian.mueller@urz.uni-  
heidelberg.de

Deadline for manuscript  
submissions:


**closed (30 September 2017)**

### Message from the Guest Editors

Dear Colleagues,

Chronic alcohol consumption is responsible for more than 200 diseases or symptoms. One of the most severe diseases associated with chronic alcohol abuse is cancer. In 2007, the International Agency for Research in Cancer (IARC) published a paper in *Lancet Oncology*, as a result of a two-week expert panel discussion that alcoholic beverages are carcinogenic. Since then, alcohol and cancer became very important topics. The purpose of this Special Issue of *Cancers* is to summarize the present knowledge regarding alcohol and cancer epidemiology and pathophysiology. The focus, however, is on mechanisms by which alcohol exerts its carcinogenic action. This up-to-date knowledge will be presented by a number of world-class experts in the field. It is our hope that the knowledge presented here may result in specific research that may contribute to the solving of many open question in the field of alcohol and cancer.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Indexed in BIOSIS Previews, Scopus and other databases.

**Rapid publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 16.9 days after submission; acceptance to publication is undertaken in 4.2 days (median values for papers published in this journal in the second half of 2018).

## Contact Us

---

*Cancers*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
www.mdpi.com

mdpi.com/journal/cancers  
cancers@mdpi.com  
@Cancers\_MDPI